Chapter 1 A Perfect World
THE ASMEDIAN EMPIREVolume One: The Birth of an Empire
ATHENASTERIA
CHAPTER ONE A PERFECT WORLD
Before the Great Collapse.
The first warning that humanity was about to destroy itself came disguised as a medical breakthrough.
Nobody noticed.
Not the governments celebrating another century of scientific advancement. Not the millions of people enjoying lives their ancestors could barely have imagined. And certainly not the women walking into the laboratories of A-TRON International, believing they were helping build a healthier future.
The world was too busy admiring itself to notice the danger growing beneath its feet.
From the eighty-sixth floor of Meridian Tower, the central continent looked almost unreal.
Silver skyscrapers pierced the morning clouds, connected by elevated walkways and transparent bridges. Residential buildings floated above artificial lakes, their foundations held in place by gravitational technology. Flying vehicles moved between designated airways, while enormous passenger trains crossed the continent at speeds that would once have seemed impossible.
The oceans were busy with automated cargo vessels. Hospitals could be transported to disaster zones. Artificial organs were manufactured in specialised laboratories, and genetic treatments had made many once-fatal diseases manageable.
Humanity had conquered almost every inconvenience it could identify.
Almost.
The world was divided into four great continents, joined by enormous bridges stretching over the surrounding oceans. The central continent was the most technologically advanced, home to nearly a hundred million people. Poverty, once considered an unavoidable feature of civilisation, had largely disappeared there.
Beyond it, the other continents followed their own rules.
Independent kingdoms, republics and empires governed their populations. Some were prosperous. Others were ruled by wealthy families who controlled resources, industries and entire cities. Technology had advanced everywhere, but equality had not.
Women had fought for centuries to claim positions that had once been reserved exclusively for men. They had become scientists, politicians, military commanders and corporate leaders. In the central continent, many of those battles had been won.
But across the world, their independence remained a source of resentment.
Some men saw progress.
Others saw a threat.
And a small group of extraordinarily wealthy men had decided that humanity needed to be corrected.
At eight in the morning, the executive elevator opened on the eighty-sixth floor of A-TRON International.
The company occupied an entire tower in the heart of the central metropolitan district. Its name appeared on hospitals, research facilities, pharmaceutical products and medical institutions across all four continents.
A-TRON had saved millions of lives.
Its fertility treatments had helped families who had spent years struggling to conceive. Its genetic research had transformed medical science, while its pharmaceutical division supplied treatments to some of the world’s largest healthcare systems.
The corporation was admired, trusted and extraordinarily profitable.
Its chairman, Lucien Voss, understood the value of that reputation.
At sixty-two, he remained an imposing man. His silver hair was perfectly arranged, his dark suit immaculate. He had the calm expression of someone who rarely needed to raise his voice to get what he wanted.
Twelve people were waiting for him in the executive conference room.
Among them was Dr. Elara Vey, one of A-TRON’s senior biological researchers.
Elara had worked for the company for eleven years. Her research into cellular adaptation had contributed to several successful treatments, and she was known for asking questions other researchers were sometimes too uncomfortable to ask.
She had not been told why she was attending the meeting.
Lucien entered and took his seat.
“Good morning, everyone.”
A holographic display appeared above the conference table.
It showed a rotating model of the human body, followed by a series of genetic sequences and biological charts.
Elara studied the information.
“What project is this?”
Lucien glanced at her.
“Project EVE.”
The name appeared across the display.
Elara frowned.
“I don’t recognise it.”
“You weren’t supposed to.”
A few people exchanged glances.
Lucien continued.
“Our latest compound has demonstrated promising results. We are preparing to expand the trials.”
“What kind of compound?”
“An advanced biological regulator.”
“Regulating what?”
“Several biological functions.”
Elara leaned forward.
“That isn’t an answer.”
A man seated beside Lucien gave a restrained smile.
“Doctor, we’re not discussing a routine pharmaceutical product. The research is highly sensitive.”
“Then I assume the documentation is available to the relevant researchers?”
Lucien folded his hands.
“You will receive access to the information necessary for your assignment.”
Elara looked at the hologram again.
There was something unusual about the biological model. The research appeared to focus heavily on female physiology.
“Why are the results separated by sex?”
“Because biological responses differ,” Lucien replied.
“Of course they do. That’s precisely why I need the complete data.”
For a moment, the room became quiet.
Lucien smiled again, but there was little warmth in it.
“You’ve always been thorough, Doctor. We value that.”
Elara didn’t smile back.
Elara’s working days were often long, but she had never considered herself particularly vulnerable to exhaustion.
That changed several months earlier.
She had been experiencing unusual fatigue, headaches and occasional dizziness. A routine medical examination showed nothing immediately concerning, and the company medical department recommended a new nutritional supplement.
It was presented as part of A-TRON’s employee wellness programme.
The capsules were small, pale and individually sealed. According to the accompanying documentation, they contained a combination of vitamins, minerals and cellular-support compounds designed to improve recovery and maintain biological balance.
Several senior employees had already been enrolled in the programme.
Elara was one of them.
She took the capsules every morning with breakfast.
She never questioned them.
Why would she?
She worked for one of the world’s most respected pharmaceutical corporations. The product had been approved by the company’s medical department, and its documentation carried the signatures of people she had known and trusted for years.
When she later discovered she was pregnant, she informed the medical department.
Her assigned physician reviewed her records and assured her that the supplements were safe to continue.
There was no reason to suspect otherwise.
Elara had no idea that the capsules contained an experimental compound associated with Project EVE.
She had already become one of its test subjects.
Three months passed.
The first reports arrived from the clinical testing programme.
Officially, Project EVE was being developed as an advanced treatment for reproductive health and biological disorders. Its participants had been recruited through selected medical institutions, and the research was being conducted under strict confidentiality.
Elara was assigned to review a portion of the results.
At first, the figures seemed ordinary.
Then she noticed something.
Several female subjects had experienced unusual muscular deterioration. Others showed significant hormonal changes. Some had developed reproductive complications that had not appeared in the original safety projections.
One subject had suffered a severe neurological reaction.
Another had remained unconscious for several days.
Elara opened the corresponding medical file.
The woman had eventually awakened, but her cognitive assessment had changed dramatically.
Elara read the report twice.
Then she opened another.
And another.
The same pattern appeared repeatedly.
She began searching the internal research archive for the original objectives of Project EVE.
Access denied.
She tried again using her senior research credentials.
Access denied.
That was when she knew the problem was bigger than a failed clinical trial.
Using an old departmental access route, she entered a restricted research directory.
The files took several seconds to load.
Then the screen filled with documents.
Financial records. Private correspondence. Internal projections. Biological assessments.
Elara’s eyes moved rapidly across the information.
The compound was not simply intended to regulate reproductive functions. It had been designed to interfere with female physical strength, fertility and neurological performance.
The intended outcome was a population in which women would become less physically capable, less fertile and, in many cases, less cognitively independent.
But the results were not entirely predictable.
Some subjects had developed severe impairments.
Others had experienced unexpected neurological changes.
One report recorded an extraordinary increase in cognitive processing.
Elara stared at the result.
“That’s impossible.”
She opened the next document.
The funding records revealed a private coalition of wealthy industrialists, political financiers and influential men. They had provided enormous sums of money to A-TRON through concealed investment structures.
Their correspondence was even more disturbing.
They believed women had gained too much influence in modern society. They regarded female independence as a threat to the traditional order and wanted to reverse the changes that had taken place over generations.
They weren’t trying to cure a disease.
They were trying to change the future of humanity.
Elara sat motionless.
For eleven years, she had worked for this company.
She had defended its research, recommended its treatments and encouraged young scientists to join its laboratories.
And now she was looking at evidence that it had been secretly developing a biological weapon against half the world’s population.
Her hands began to shake.
She scrolled further.
A document near the bottom of the archive caught her attention.
PROJECT EVE: GLOBAL ADMINISTRATION STRATEGY.
The proposed release plan had already been approved.
The compound would be introduced through a series of medical programmes across multiple continents. Its administration would be disguised as a public-health initiative.
The first phase was scheduled to begin soon.
Elara felt the blood drain from her face.
They weren’t planning to stop.
They were planning to distribute it.
“Dr. Vey?”
She nearly dropped her device.
Director Halden stood in the doorway.
He was responsible for internal research security and had a reputation for appearing whenever someone accessed information they weren’t supposed to see.
Elara closed the files.
“Yes?”
“I noticed some unusual activity on your account.”
“I was reviewing clinical records.”
“Which records?”
She hesitated for only a second.
“Project EVE.”
Halden’s expression changed.
It was subtle, but she noticed.
“That project is no longer within your department.”
“I wasn’t aware of that.”
“Well, now you are.”
Elara turned her chair towards him.
“Why are the test results being concealed?”
“They aren’t.”
“Then explain the neurological damage.”
“Early clinical trials sometimes produce unexpected results.”
“And the reproductive damage?”
“That is being investigated.”
“Without informing the subjects?”
Halden closed the door.
“Lower your voice.”
Elara stared at him.
“You’re telling me women are being exposed to a compound without knowing what it does, and you expect me to lower my voice?”
He stepped closer.
“You need to understand that there are people involved in this project whose authority extends far beyond this building.”
“That doesn’t make it right.”
“Right and wrong are not always relevant to the decisions that shape civilisation.”
For a moment, Elara couldn’t believe what she had heard.
“You’re serious.”
“Delete the files you accessed. Forget what you saw. Continue with your assigned work.”
“And if I don’t?”
Halden looked at her for several seconds.
“Then you will make this much more difficult than it needs to be.”
He left without another word.
Elara remained seated, staring at the closed door.
She had spent years believing that intelligence, evidence and reason could solve almost any problem.
Now she understood that some people had already decided what they wanted, and they were willing to destroy anyone who stood in their way.
That evening, Elara returned to her apartment and locked the door.
She sat at her kitchen counter, staring at the capsules in their little container.
For the first time, she wondered whether she had ever been given the truth about them.
She picked up the container and turned it over.
The ingredients were listed in precise medical language. Nothing looked unusual. Nothing indicated the presence of an experimental compound.
She opened her personal medical record and compared the supplement’s batch number with the employee wellness programme documentation.
Then she remembered something.
A few weeks earlier, she had requested an adjustment to her dosage after experiencing dizziness. The medical department had told her the formulation was being updated.
She had accepted the replacement without question.
Her fingers moved quickly across her device.
She entered the batch number into the internal research archive.
The result was restricted.
She tried another route.
This time, the system returned a partial reference.
EVE-09: CONTROLLED INTERNAL ADMINISTRATION.
Elara stopped breathing.
The capsules were part of the experiment.
She looked down at the container.
She had swallowed them every morning.
Even after discovering her pregnancy, she had continued taking them because her assigned physician had assured her they were safe.
A cold wave passed through her body.
She opened her personal medical application and requested an emergency genetic and toxicological assessment.
The appointment was confirmed for the following morning.
The examination took place at a private medical centre in the eastern district.
Elara arrived before sunrise. She gave the physician her medical history, explained the supplements and requested a full assessment of her biological markers.
The doctor examined the results in silence.
“Is something wrong?” Elara asked.
“I’m seeing an unusual response.”
“What kind of response?”
The doctor enlarged a section of the genetic scan.
“Your cellular adaptation markers are significantly outside the expected range.”
“Could it be the medication?”
“Possibly. I would need to compare your earlier records.”
Elara leaned forward.
“And the pregnancy?”
The doctor paused.
“The pregnancy is progressing, but the developing foetus is showing some unusual biological activity.”
Elara felt her stomach tighten.
“What does that mean?”
“I can’t give you a definitive answer yet.”
“Is my baby in danger?”
“I don’t know.”
The words struck harder than any diagnosis.
The doctor continued examining the results.
“There is something else. Your biological markers appear to be changing in a way I haven’t encountered before. I recommend that we monitor you closely.”
Elara looked at the screen.
For a brief moment, one of the readings fluctuated sharply.
Then it disappeared.
The physician frowned and repeated the scan.
The result was normal.
“Perhaps a scanner error,” he muttered.
Elara said nothing.
She was thinking about A-TRON.
About the capsules.
About the women in the clinical reports.
She had spent years studying biological adaptation. She knew that the human body could respond unpredictably to experimental compounds.
But this was different.
She was not simply a researcher examining a medical problem.
She was part of it.
And the child she was carrying might be part of it too.
Later that day, Elara accessed the encrypted files she had copied from A-TRON.
She found a document containing the internal breakdown of the compound.
Most of its intended effects were familiar by now: suppression of reproductive function, deterioration of physical strength and interference with neurological performance.
But one section described a rare phenomenon observed during early testing.
UNEXPECTED ADAPTIVE RESPONSE.
The compound could trigger unusual biological changes in a very small number of subjects. The researchers had not identified a reliable pattern or a predictable outcome.
One of the notes suggested that certain developmental conditions might produce a response different from the intended suppression.
Elara read it repeatedly.
She looked at her medical results.
Then at the pregnancy report.
She did not understand what was happening.
She did not know that the compound had begun interacting with the developing child in a way A-TRON had never anticipated.
She did not know that the child’s biological development was beginning to diverge from every established human classification.
And she certainly did not know that the strange readings on the medical scanner were the earliest evidence of something extraordinary.
The following morning, Elara made her decision.
She would disappear.
She had no family to turn to. She had grown up without parents, and there were few people who could trace her personal history.
For the first time, that absence might save her life.
She began making preparations.
Her professional identity would have to be abandoned. Her apartment, her research position and the life she had built over eleven years would all become liabilities.
She would need another name.
Another home.
Another life.
Before leaving, she saved the evidence she had gathered in several encrypted locations.
If anything happened to her, someone needed to know what A-TRON had done.
But she would not risk exposing her child by attempting to confront the corporation herself.
Outside, the city was glowing beneath the morning sky. Flying vehicles crossed between the towers. Restaurants were filling with people. Families walked along the illuminated waterfront.
Everything was peaceful.
Everything was normal.
And somewhere inside A-TRON International, the final preparations for Project EVE continued.
The corporation believed it was preparing to reshape humanity.
It had no idea what it had already created.
Elara stepped into the street and disappeared into the morning crowd.
She had no idea that the compound would eventually escape the control of the people who created it.
She had no idea that its effects would reach far beyond human biology, transforming animals, altering the environment and changing the course of civilisation.
She had no idea that the child growing inside her would become something the world had never seen before.
She only knew one thing.
Her child would not belong to A-TRON.
And if the world came looking for them, it would have to search for a woman who no longer existed.
END OF CHAPTER ONE










